Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Posted by George Bondi on May 30th, 2026

Champions Oncology, Inc. (NASDAQ:CSBR – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.37 and traded as low as $5.70. Champions Oncology shares last traded at $5.85, with a volume of 20,938 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Our Latest Report on Champions Oncology

Champions Oncology Stock Performance

The company has a market cap of $81.12 million, a P/E ratio of -36.50 and a beta of 0.42. The stock has a 50-day moving average of $5.97 and a two-hundred day moving average of $6.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in Champions Oncology during the 2nd quarter valued at approximately $103,000. Essex Investment Management Co. LLC purchased a new stake in Champions Oncology during the 4th quarter valued at $126,000. Jane Street Group LLC purchased a new stake in Champions Oncology during the 1st quarter valued at $200,000. Goldman Sachs Group Inc. purchased a new stake in Champions Oncology during the 1st quarter valued at $201,000. Finally, Acadian Asset Management LLC boosted its stake in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. Institutional investors own 41.30% of the company’s stock.

Champions Oncology Company Profile

(Get Free Report)

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.